"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Good morning. My name is Carla and I will be your conference operator today. Today's conference is being recorded. At this time, I would like to conclude everyone to the Sigma-Aldrich fourth quarter 2009 results conference call. All lines have been placed",81,"Good morning. My name is Carla and I will be your conference operator today. Today's conference is being recorded. At this time, I would like to conclude everyone to the Sigma-Aldrich fourth quarter 2009 results conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. (Operator instructions)
I will now turn the call over to Mr. Kirk Richter, Treasurer and Investor Relations contact. Please go ahead, sir.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you and let me also say good morning and welcome you to Sigma-Aldrich's fourth quarter 2009 earnings conference call. With me today are Jai Nagarkatti, our Chairman, President and Chief Executive Officer and Rakesh Sachdev, our Senior Vice President",316,"Thank you and let me also say good morning and welcome you to Sigma-Aldrich's fourth quarter 2009 earnings conference call. With me today are Jai Nagarkatti, our Chairman, President and Chief Executive Officer and Rakesh Sachdev, our Senior Vice President and Chief Financial Officer.
After my introductory comments, Rakesh will review our fourth quarter and full year 2009 performance and our outlook for 2010. Jai will follow that with additional comments on our 2009 performance and review of the activities we have planned for 2010 to achieve our financial expectations and position our company for sustained longer term growth.
After completing these reviews, we will open up the call for your questions and comments. We will be using a slide presentation of part of today's call. That presentation can be viewed by accessing our Investor Relations website on sigma-aldrich.com.
Before we begin our reviews, I do need to remind you that today's comments will include forward-looking statements about future activities and our expectations for sales, earnings, cash flow and other possible future results. While we believe these expectations are based on reasonable assumptions, actual results may differ materially due to any number of factors including the risk factors listed in our Annual Report on form 10-K for the year ended December 31st, 2008 and in the cautionary statement that is included in today's release and in our slides. We have no plans to update these forward-looking statements after this conference. Also, SEC regulations require us to provide information on any non-GAAP financial measures covered in today's conference. That information which consists of currency and acquisition adjusted sales growth, profit and EPS results on both a pro forma and reported basis and free cash flow reconciled to net cash provided by operating activities is also contained in today's earnings release which is posted on our website.
Now, I will ask Rakesh to begin our review. Rakesh?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks, Kirk and good morning to all of those on the call today. I am pleased to tell you that our fourth quarter sales and earnings results were better than any of the previous quarters this year. While our markets improved slightly, our efforts to drive",1530,"Thanks, Kirk and good morning to all of those on the call today. I am pleased to tell you that our fourth quarter sales and earnings results were better than any of the previous quarters this year. While our markets improved slightly, our efforts to drive our own growth above market rates were meaningful contributors to this achievement.
As indicated in today's earnings release, fourth quarter sales were $573 million, our best quarter in 2009, due to both improved organic growth over prior quarters and a positive currency contribution. Our fourth quarter net income of $93 million and diluted earnings per share of $0.75 also exceeded our results in each of the first three quarters of the year.
And finally, our free cash flow in the fourth quarter of $122 million was the best quarterly result in the last eight quarters. Reported sales for the fourth quarter were 12% higher than last year's fourth quarter, with equal contributions from currency and organic sales growth.
While currency contributed to our sales growth, it remained a head wind at the bottom line, reducing our otherwise reportable fourth quarter net income by $7 million or our diluted EPS by $0.06. Consistent with the earlier quarter of 2009, we were again able to offset that currency impact and report higher net income and EPS in this year's fourth quarter compared to last year's.
Our pretax income in the fourth quarter also includes a $9 million restructuring charge to consolidate some facilities in our SAFC business and the cost of a voluntary retirement program. These restructuring activities are meant to increase the efficiencies of our operations and lower our overall fixed cost structure.
Our fourth quarter net income and diluted EPS, exclusive of the currency impact was up 18% and 19% respectively from last year's fourth quarter as we delivered process improvement benefits through our supply chain and other initiatives from managed costs to offset that currency impact.
While our restructuring charges reduced our otherwise reportable EPS by $0.05, we gained about $0.04 from a lower than normal tax rate. These essentially offset each other. I will have more comments on these results shortly.
Finally, we generated strong free cash flow of $122 million in the fourth quarter, assisted by $33 million in reduction of inventories.
We go to the next slide. The positive contribution to sales from currency and organic growth in the final quarter of 2009 provided a substantial improvement in our reported sales performance for the full year, driving down the decline of 7% we experienced for the first nine months of 2009 to a decline of 2% for the full year. And we expect some of that momentum to carry into 2010 making us comfortable with our forecast of mid-single digit organic sales growth for this year.
Our full year reported net income and EPS were negatively impacted by unfavorable currency movements amounting to $50 million or $0.40 when compared to the prior year. This was more than offset by benefits from our supply chain initiatives, lower SG&A costs and favorable pricing. While our fourth quarter EPS saw only a modest benefit from our share repurchases, that activity did provide a $0.09 benefit for the full year.
Strong generation of free cash flow in the fourth quarter drove the full year results to $396 million which was an $82 million improvement from last year. This was despite a $30 million increase in capital investments in 2009. Inventory management was a large driver of our free cash flow improvement.
In 2008, we used $38 million of cash to fund growth in inventory compared to $71 million of cash generated from reduction in inventories in 2009. That inventory change came from our efforts to more actively manage inventory levels, enabling us to reduce our months on hand from seven months a year ago to 6.5 months at the end of 2009. While not at the same levels, we expect further reductions in 2010.
Let's now review our sales performance for the fourth quarter and full year of 2009 in more detail. Organic growth and research sales in the fourth quarter reflects improved performance in each of our research-based businesses. In particular, we saw strength in sales of analytical products offered by research specialties business unit, also in Q4, our research Biotech business saw its highest quarterly sales growth in 2009, fueled by our synthetic DNA and molecular biology products.
Geographically, modest improvements in sales and the U.S. and European markets were supplemented by continued stronger growth from our CAPLA or Canadian Asia Pacific and Latin American markets. Research sales to Universities continued to be stronger than sales to commercial accounts towards last year.
In SAFC, Q4 was the best quarterly performance in 2009. Meeting early expectations for improved sales in the final quarter of 2009. Improved performance for our custom pharma and biosciences products was driven by continued demand for adjuvant products for the H1N1 vaccine production and industrial media for pharmaceutical customers, as well as customer efforts to push early stage clinical trials in response to indications of moderate economic improvements.
An improvement in demand for our niche high tech products for the solar and semi conductor industries also drove the higher growth for SAFC in Q4. Our booked orders for future delivery increased by 9% over the level at the end of September 2009 and by 16% from the level coming into 2009.
Geographically, modest improvements in sales in the U.S. and Europe were supplemented by continuous strong growth from Asia Pacific and Latin American markets. As you can see in our margin analysis, our reported overall pretax margin for Q4 was just slightly above where it was in last year's fourth quarter. We again faced currency headwinds relative to last year's fourth quarter that reduced our margin by 3.2%. Favorable pricing and the increased volumes were more than sufficient to offset modest margin dilution from the higher mix of SAFC sales. The $9 million restructuring charges reduced otherwise reportable margins also by about 1.8%. But as we have done throughout 2009, we were again able to offset these impacts with our supply chain process improvement initiatives and reduction in SG&A spending.
As I mentioned earlier, we continue to generate strong free cash flow with the $396 million achieved in 2009, representing a new record and a 26% improvement over what we achieved in 2008. Our working capital management initiatives, particularly in managing our inventory, are now fully implemented across our global organization and are achieving results we expected when we launched them over two years ago. There is still more room for improvement as we plan to continue our momentum to reduce our inventory levels from the 6.5 months of inventory we held at 2009 year end.
Capital spending for 2009 was $120 million, as we completed expansions in Israel and the U.S. earlier than expected and launched projects to expand our packing and distribution capabilities to support the faster growth we have experienced in India and China. Consistent with prior reports we have not encountered any change in our ability to place short-term debt in the U.S. or international markets.
As you may know, $100 million of our debt is due in September of 2010 so we will evaluate our borrowing needs and structure in the coming months. We feel we have a strong balance sheet and have sufficient cash and borrowing capacity to adequately fund our operations and make selective acquisitions. Our sales growth expectation for 2010 reflects the market improvement we saw late in 2009. Our continued efforts to take market share from new initiatives that Jai will comment on shortly.
While we expect continued improvement in market conditions, we remain a little cautious, not expecting market growth to return to its historical rate of roughly 5% in 2010. With this expected market improvement and our efforts to build on that with innovation in our product and service offerings, we expect our organic sales growth to improve from the low single digit growth in 2009 to something in the mid-single digits for 2010. If currency rates remain at current levels, we expect it will add approximately 1% to that organic growth. Diluted EPS is expected to be in the range of $3 to $3.15.
To achieve that, we again expect to improve pretax margins by continuing our supply chain optimization initiatives and realizing benefits from higher sales volumes. We expect to take additional charges of approximately 22 million over the next 18 months related to these restructuring actions. One fully implemented, we expect annual savings of approximately $15 to $20 million.
We expect minimal savings in 2010 as these actions will not be fully implemented until 2011. Currency is expected to contribute about $0.10 to this diluted EPS forecast if rates remain at current levels. Our effective tax rate for 2010 is expected to be in the 30 to 31% range as we don't expect the tax benefits realized in 2009 to repeat, given that the U.S. government has not extended the R&D tax credit for 2010 at this time.
Now, I will ask Jai to comment on our accomplishments in 2009 and our 2010 forecast. Jai?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you, Rakesh. Good morning, everyone. I am pleased to support what you have already heard from Rakesh about our ability to deliver improved performance in the fourth quarter in what remained a challenging economic climate. We saw continued positive b",1453,"Thank you, Rakesh. Good morning, everyone. I am pleased to support what you have already heard from Rakesh about our ability to deliver improved performance in the fourth quarter in what remained a challenging economic climate. We saw continued positive benefit from a number of initiatives that we launched at the beginning of the year. And our SAFC business delivered strong positive organic sales growth for the second successive quarter.
Let me review just a few highlights in our fourth quarter performance that we believe provide support for our 2010 expectations and guidance. Our research Biotech focus on our largely recession resistant academic and government research institute customers helped achieve the highest year-over-year quarterly sales growth this year.
Our focus on innovation and new to the world product that helps to create demand was evident by the launch of over 15,000 new antibody products this year. We launched other novel products in areas of research such as transgenic animal models and products used for research and development in regenerative medicine and epigenetics.
Examples of these products include high stem, a fully customizable, synthetic extra cellular matrix for stem cell research, StemGen's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem cells and our award-winning transgeneics stage speed custom knockout rat program, leveraging our Zinc Finger Nuclease Technology.
We are pleased that our innovative offering in science are being recognized in the marketplace with the most notable in fourth quarter being the Scientist magazine placing the gene knockout rat program among the top five innovations in 2009.
Sales to our e-commerce channel continued to grow over last year's fourth quarter and represented 45% of our research sales in the fourth quarter, up from 42% one year ago. We have increased the average number of new registrations each month from 20,000 in the third quarter to about 24,000 in the fourth quarter which is a 20% increase in just one quarter.
We also added over 100 new direct business-to-business connections in 2009. We had a new record of over 3 million visits to our website in October 2009 with an average monthly increase of 10% from the prior year level. And we have now added access capabilities on Facebook for some of our key research engines like 'Your Favorite Gene'.
In international markets, fourth quarter organic sales in the CAPLA countries again exceeded the growth rates for our other geographic regions. Excluding the impact of currency, fourth quarter 2009 sales growth in this region grew by 9%, with research sales growth in the mid-single percentage range, bolstered by organic growth for SAFC in the mid-20% range.
In our focus markets of India, China and Brazil, overall organic growth in the fourth quarter was 18% with organic sales growth in the individual countries ranging from between 12 to 33%.
Within our SAFC unit, we continued to see a strong indicator of future growth in our booked orders for future delivery. We delivered a fair amount of what we booked at September 30 in the fourth quarter and our order book remains about 9% higher than it was at the end of September and 16% above the level at the end of 2008. Thus this is a positive indicator for improved performance from this unit in 2010.
Our supply chain initiatives continue to be an important contributor to our improved profitability and ability to offset the currency head wind. We achieved about another $4 million in pretax benefits in the fourth quarter, bringing the year-to-date total savings from this initiative to $22 million.
For both the fourth quarter and full year, this supply chain benefit, coupled with our cost management initiatives and a contribution from our share repurchase program, enabled us to more than offset the currency impact on our earnings per share that were $0.06 for fourth quarter and $0.40 for the full year and a $9 million restructuring charge in the fourth quarter.
Let me now recap our financial reserves for the full year of 2009. On a reported basis, our sales were off 2%, but we did increase our organic sales by 2% as well. More importantly, we were able to offset the currency impact in earnings per share as we delivered 6% increase in reported value to the EPS, for all of 2009 which equals a 21% increase exclusive of currency impact.
That makes 35 consecutive years of earnings per share increases. That performance also enabled us to maintain our compound growth in diluted earnings per share in the low double-digits range for the last five years and we have also maintained that growth consistently in our dividend payout over the same period.
And I can't overlook the new record in free cash flow that we achieved in 2009. Rakesh commented on the details previously, but the new record of $516 million in cash from operations enabled us to continue investing in our future growth with a $30 million increase in capital expenses in 2009, as well as maintaining our funding of research and development and allowed us to invest $50 million in technology and geographic expansion to acquisitions, strategic partnership and licenses.
But what do these achievements indicate about our ability to improve on this for 2010? Sure, our markets are expected to improve, but we also added about 40,000 new products in 2009 and another 4,000 customer accounts. The increased product offering includes about 15,000 new antibody products and 10,000 new disposable equipment items. But that's just the beginning of what we expect to drive our growth in 2010.
We will continue to expand our capabilities to build on the differentiation we already have in the life science and high technology markets which we serve. We have a long history of successfully serving the research and fine chemical markets with leading products, services and technical support. Our broad scientific knowledge encompasses analytical, biology and chemistry products.
In the analytical area, we are focused on the faster growing segments of environmental, food safety, bioanalytical testing and standards. In biology our goal is to be the leading destination police for life science research to access both products and information to solve the complex biological questions.
We are rapidly building strong capabilities in Zinc Finger Nuclease technology and our antibody content and offering. We have a strong presence in the chemistry market that is income versus lab essentials, organic specialties and material science products. We expect stronger growth in all application areas in material science, utilizing our unsurpassed knowledge of organic and Organometallic Chemistry. We're a leader in Boron Chemistry and have products used in hydrogen storage and other electronic and technical applications.
In electronics our chemicals replace metals in semiconductors and are used to improve the clarity of surface data. Our care sensitive products are used in numerous high tech applications. We produce over 48,000 organic chemicals and biochemicals in both research and manufacturing quantities which is the largest number of products produced by any single company anywhere in the world, giving us access to unrivaled scientific knowledge. And we feel that our scientific information library is second to none which includes knowledge of the sources of every commercially available chemical and how to ship, store and use them in a safe and compliant manner.
What gives us the confidence that we can deliver on our commitments and achieve the growth we expect? Our markets are large and growing faster in some of the emerging international markets and we expect that they will continue to do that in the future. We plan to continue to expand our global reach, I have just outlined the product capabilities that are expected to contribute to the growth and we have 7,700 dedicated employees around the globe who share common values and are eager to support these goals.
That now brings me back to a forecast for 2010. Rakesh has already discussed our current expectations of mid-single digit organic sales growth, diluted earnings per share in the range of $3 to $3.15 and free cash flow in excess of $350 million. Let me assure you that the entire Sigma-Aldrich team is committed to achieving these results and I look forward to updating on you our progress in the next conference call.
I want to thank you for your ongoing interest in our company. We are focused on creating differentiation through our innovative efforts as we seek to be a leader in the life science and high technology markets and deliver superior returns for our employees and our investors.
On behalf of my colleagues, Rakesh and Kirk and our colleagues around the world, I want to thank you for joining us today. Now let's open up the call for your comments and questions. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Thank you. (Operator instructions) Our first question comes from Jon Wood with Jefferies.",13,"Thank you. (Operator instructions) Our first question comes from Jon Wood with Jefferies.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey, thanks a lot. Good morning.",6,"Hey, thanks a lot. Good morning.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Good morning, Jon.",3,"Good morning, Jon.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey, Rakesh, your guiding CapEx above the historical range is again in 2010 after there is some discrete projects I realize in 2009, can you kind of give us a sense of what you are spending this year and what the outlook is beyond 2010?",45,"Hey, Rakesh, your guiding CapEx above the historical range is again in 2010 after there is some discrete projects I realize in 2009, can you kind of give us a sense of what you are spending this year and what the outlook is beyond 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Sure. So as you rightfully pointed out, we had some discrete large projects in 2009 and just to reiterate, we expanded our operations in Madison, in Wisconsin and Israel and some in California. Looking ahead, we have got some other additional projects tha",171,"Sure. So as you rightfully pointed out, we had some discrete large projects in 2009 and just to reiterate, we expanded our operations in Madison, in Wisconsin and Israel and some in California. Looking ahead, we have got some other additional projects that have some anticipated restructuring.
There is also, our supply chain efforts as you know we do a lot of work in capitalized some software, so there is some work going on there, so we have again I think two or three sort of large things that will pay some very significant dividends for the company and the rest of it, typically what we will have in about $130 million about 50 or 60 that we would spend on normal sort of running the business and then we would typically somewhere between $40 million to $60 million of major programs that are either addressing efficiency issues or new products or some restructuring. We will bring you more clarity as the year goes and we announce some of those things.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Should we expect CapEx to fall in 2011 as some of these projects are completed?",15,"Should we expect CapEx to fall in 2011 as some of these projects are completed?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think going forward you can expect our CapEx to stay in the range of somewhere in the 4.5% of sales, 4, 4.5%.",24,"I think going forward you can expect our CapEx to stay in the range of somewhere in the 4.5% of sales, 4, 4.5%.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Great. And then it looks like product mix negatively impacted your gross margins by around 200 basis points in 2009. Can you comment on your expectations for mix in 2010?",31,"Okay. Great. And then it looks like product mix negatively impacted your gross margins by around 200 basis points in 2009. Can you comment on your expectations for mix in 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Well. Actually if you look at margins in 2009, a big head wind on margins was currency. I think almost over 200 basis points of margin was knocked out from compared to 2008 due to currency. Now, we offset that more than offset that by our savings and supp",127,"Well. Actually if you look at margins in 2009, a big head wind on margins was currency. I think almost over 200 basis points of margin was knocked out from compared to 2008 due to currency. Now, we offset that more than offset that by our savings and supply chain and SG&A.
I think we picked about close to 250 basis points margin in 2009 alone from our SG&A savings and supply chain, so I think on our pretax basis we reported in 2008 22.2% margin and in 2009, we report 22.8%. So we actually on a reported basis have a 60 basis point margin improvement, despite over 200 basis points reduction from currency, so I thought it was a fabulous year from that standpoint for us.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Sounds good. And then Jai, would you comment on SFAC, do you expect the benefits from the flu to persist in the first half of 2010? And then can you discuss your outlook for the industrial cell culture business in 2010?",42,"Okay. Sounds good. And then Jai, would you comment on SFAC, do you expect the benefits from the flu to persist in the first half of 2010? And then can you discuss your outlook for the industrial cell culture business in 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Okay. I think the benefit from H1N1 in 2009 was tremendously appreciated that. Obviously, going into 2010 in the first quarter we may get some benefit but we'll not get the overall benefit for the year. We don't expect under some other epidemic breaks out",112,"Okay. I think the benefit from H1N1 in 2009 was tremendously appreciated that. Obviously, going into 2010 in the first quarter we may get some benefit but we'll not get the overall benefit for the year. We don't expect under some other epidemic breaks out and we get more orders. But we will also realize even before 2009 we always had products, which we supported for vaccine manufacturing, so to that extent we can expect to see continued orders for that product line. I want to also comment that regardless of what we benefited in 2009 no single product, including products for H1N1 accounted for more than 1% of our total sales.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Can you discuss the industrial cell culture outlook for 2010?",11,"Okay. Can you discuss the industrial cell culture outlook for 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","The industrial cell culture - in fact the industrial cell culture business in 2009 we saw good promise and progress as both projects, which started going to the pipeline continued to accelerate and we started providing more media. So I think we saw growth",55,"The industrial cell culture - in fact the industrial cell culture business in 2009 we saw good promise and progress as both projects, which started going to the pipeline continued to accelerate and we started providing more media. So I think we saw growth and we expect to continue to see growth in 2010 as well.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thanks a lot.",4,"Okay. Thanks a lot.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","And now we'll hear from Quintin Lai with Robert Baird.",11,"And now we'll hear from Quintin Lai with Robert Baird.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hi, good morning.",3,"Hi, good morning.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Good morning, Quintin.",3,"Good morning, Quintin.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","First with respect to your comments about stimulus and the modest I guess expectations that is kind in line with a lot of what the other tools companies. Could you provide a little bit it more color, Jai on kind of your expectations over either 2010 and 2",51,"First with respect to your comments about stimulus and the modest I guess expectations that is kind in line with a lot of what the other tools companies. Could you provide a little bit it more color, Jai on kind of your expectations over either 2010 and 2011 for the stimulus?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think Quintin has we said earlier we did not count significantly on the stimulus money to contribute to the growth. Now, if it comes obviously we'll be glad to take it. Where we are seeing some interest really is in some of our newer technologies and ca",143,"I think Quintin has we said earlier we did not count significantly on the stimulus money to contribute to the growth. Now, if it comes obviously we'll be glad to take it. Where we are seeing some interest really is in some of our newer technologies and capabilities that we have added such as the Zinc Finger Nuclease and the knockout models. The orders that we are getting for those types of innovative products appears to be connected to the stimulus money.
So I think obviously this is new innovative technology. We are very high on that and we expect that as 2010 and as we get into 2011, we should start seeing increased benefits. Now again, I come back to the original statement that I made. Even Zinc Finger Nuclease technology products don't account for more than 1% of our sales. Certain…
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you very much for that. With respect to your exposure to foreign currency, you did an excellent job of offsetting foreign currency headwinds with things like your supply chain initiative. Now as the dollar weakened in the back half of the year, we s",109,"Thank you very much for that. With respect to your exposure to foreign currency, you did an excellent job of offsetting foreign currency headwinds with things like your supply chain initiative. Now as the dollar weakened in the back half of the year, we should probably see some benefit to the operating margins in the first half of 2010. But now the dollar is starting to get volatile again, so the question is that with the volatility in the dollar these days. How much runway do you have to monitor your cost controls and to offset let's say potential headwinds to say maybe in the back half of 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yeah. Quinton, this is Rakesh. Clearly, the dollar has been very volatile and even from the December levels, as - with what's happening in Europe and the discussions around several countries there that has caused the euro to get weaker. Just to give you a",221,"Yeah. Quinton, this is Rakesh. Clearly, the dollar has been very volatile and even from the December levels, as - with what's happening in Europe and the discussions around several countries there that has caused the euro to get weaker. Just to give you an idea, the average I think the euro rate for 2009 was about $1.47 compared to a, sorry, $1.39 compared to about $1.47 in the previous years and I think similar levels. So if the exchange rate remains at similar levels, I think as we gave in the guidance we should still have a slight benefit in 2010.
Now, we are going - we are proceeding on a longer journey of trying to build a natural hedge, so some of the restructuring we are doing and some of the new businesses that we're getting in future expansions of where we put our investments is going to start creating a natural hedge. So that exposure over time will go down. There is not much we can do with the external environment, with what's happening and we just watch that rate carefully and we try and react to it in a proper fashion and we will do the same. I mean our commitment is trying to offset whatever we can within the bounds of reasonable movements and exchange rates.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Well, I guess going back to something you said last year, Rakesh, that some of the costs initiatives, some of them more permanent, some of them you expect to maybe a re-inflation of cost in 2010. I guess it's that latter half, is there a variable componen",65,"Well, I guess going back to something you said last year, Rakesh, that some of the costs initiatives, some of them more permanent, some of them you expect to maybe a re-inflation of cost in 2010. I guess it's that latter half, is there a variable component that in the event of maybe an FX headwind that you could maybe delay the re-inflation of costs?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think we can, yes. So - in fact as I said we will be very prudent before we open the tap to start spending more we will kind of watch and see what's happening with volatility. But we absolutely are in control of that, a lot of that. Now, some of that we",114,"I think we can, yes. So - in fact as I said we will be very prudent before we open the tap to start spending more we will kind of watch and see what's happening with volatility. But we absolutely are in control of that, a lot of that. Now, some of that we're going to allow for the spending to take place, for example, last year we didn't get merits to our people so we going to go ahead and do that. So there are some things we will do. There are several other areas where we will monitor and see what's happening in the external environment and decide whether we delay that.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Thank you.",3,"Great. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks.",1,"Thanks.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now we'll hear from Mike Sison with KeyBanc.",9,"Now we'll hear from Mike Sison with KeyBanc.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey, guys. Congrats on a very good end to the year.",11,"Hey, guys. Congrats on a very good end to the year.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Hey, thanks, Mike.",3,"Hey, thanks, Mike.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Jai, can you sort of revisit some of your long-term goals for organic sales growth by segment and I guess I am just wondering you sort of take a look at the downturn and maybe discuss what if any structural changes that the downturn has caused in terms of",83,"Jai, can you sort of revisit some of your long-term goals for organic sales growth by segment and I guess I am just wondering you sort of take a look at the downturn and maybe discuss what if any structural changes that the downturn has caused in terms of your customers, the way they buy or maybe some of your markets that maybe could I am bead your ability to hit that sort of mid to high single-digit organic sales growth over time?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Mike, thank you first and then see our goal always has been to continue to expand and grow faster than the markets, at least by 100 to 200 basis points faster than the markets have been growing. Now, how do we do that? Obviously there are price element wh",220,"Mike, thank you first and then see our goal always has been to continue to expand and grow faster than the markets, at least by 100 to 200 basis points faster than the markets have been growing. Now, how do we do that? Obviously there are price element which is small but going forward I think the goal is to create demand by adding products that are enabling by putting more innovative products, following the direction of research to see, which type of products are likely to be used. So great focus leveraging our knowledge of chemistry, the context that we have in the industry and in academic institutions, the licensing in the partnership that we do, the key is to put products that will enable us to create demand.
Now, having said that, we also know that 2008 and '09 were unusual years where all geographies were hit by the economic uncertainty. Historically, what we have found is because of the diversification and the way we are supporting research throughout the world. There are opportunities in the faster growing economies because of the presence that we have, the investments that we have made in planning to make, we should I feel comfortable, we feel comfortable that we should be able to take share and grow faster in the market.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Great. And then in terms of your supply chain initiatives, great job again in 2009. That was a program that was supposed to go through 2012. Are you ahead there or is the number going to be actually bigger at the end of the day in terms of what you",57,"Okay. Great. And then in terms of your supply chain initiatives, great job again in 2009. That was a program that was supposed to go through 2012. Are you ahead there or is the number going to be actually bigger at the end of the day in terms of what you can generate in terms of savings?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","That's a good question, Mike. I believe we said we guided the street and told you that we expected to get about 150 basis points improvement in margins from supply chain. Obviously, as we said in the call this past year that we were accelerating that, we",158,"That's a good question, Mike. I believe we said we guided the street and told you that we expected to get about 150 basis points improvement in margins from supply chain. Obviously, as we said in the call this past year that we were accelerating that, we were feeling quite confident that we were moving at a pace faster. In fact, just to tell you, we have achieved 120 basis points improvement in margin from supply chain initiative alone in 2009.
So that's a huge number that we got. So as I mentioned on an earlier comment, that was a fabulous year for us. Now, we will meet the 150 and with the additional restructuring that we have announced we will see further margin expansion. Now, that the restructuring benefits are not likely to come in 2010, but we will see that kick up in 2011. We have other things we're working on to continue this journey.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Great. And then last question, just curious on the high tech side, an area that you highlighted in terms of new sales initiatives. Are you going to be sort of expanding solar or other new markets like LEDs or something you are going to really focus",60,"Okay. Great. And then last question, just curious on the high tech side, an area that you highlighted in terms of new sales initiatives. Are you going to be sort of expanding solar or other new markets like LEDs or something you are going to really focus in on or in terms of new technology that will drive growth there?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Mike, again this is Jai. I think our ability to handle air sensitive chemistry because a lot of the product that is go in the high tech applications. The basis of that are in the high tech chemistry, I mean air sensitive chemistry, Sigma-Aldrich particula",145,"Mike, again this is Jai. I think our ability to handle air sensitive chemistry because a lot of the product that is go in the high tech applications. The basis of that are in the high tech chemistry, I mean air sensitive chemistry, Sigma-Aldrich particularly the Aldrich brand has been really strong in this and as we are learning that there are more and more applications for these type of products. The exposure to these type of industries in terms of the new products that we bring is getting a lot of interest and generate ago lot of interest. I should also say at this point very few of the products have gone into commercial applications, still being used in the development tool and process work that many of the companies are doing in various applications and we will aggressively push this in these markets.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Thank you.",3,"Great. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks, Mike.",2,"Thanks, Mike.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","And now we'll open the floor up to Dan Leonard with First Analysis.",14,"And now we'll open the floor up to Dan Leonard with First Analysis.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you. I have two questions. One, you made the comment in the press release that you expect pharma spending to increase in 2010. Why do you expect pharma spending to increase?",32,"Thank you. I have two questions. One, you made the comment in the press release that you expect pharma spending to increase in 2010. Why do you expect pharma spending to increase?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think a couple of things. When we use the word pharma, Dan, it's just actually both small and large pharma. What we are beginning to see is a number of projects at least based on the inquiry that is we are getting for custom work for the pharma is certa",132,"I think a couple of things. When we use the word pharma, Dan, it's just actually both small and large pharma. What we are beginning to see is a number of projects at least based on the inquiry that is we are getting for custom work for the pharma is certainly getting better every quarter-over-quarter. That's number one.
The second thing which we are also finding is the biopharma companies, somebody asked a question on the industry cell culture and number of projects that we got into the pipeline early on last several years are continuing to increase and expand as these companies are trying to accelerate getting these products to market. So we certainly expect that to be contributing factors in smart pharma spending that we can support and benefit from.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thank you. And then my second question, Jai, you have historically been rather shy about showing margin growth than came your supply chain initiative and now you announced additional restructuring. So when I think about your business, are you guys g",62,"Okay. Thank you. And then my second question, Jai, you have historically been rather shy about showing margin growth than came your supply chain initiative and now you announced additional restructuring. So when I think about your business, are you guys going to be managing your business to drive margin improvement on a consistent basis annually over a multi-year period going forward?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think, Dan, our priority really is to grow top line first. That so we will not do anything at the expense of jeopardizing consistent long-term top line growth, which grows faster than the market. Now, having said that we will obviously as an organizatio",144,"I think, Dan, our priority really is to grow top line first. That so we will not do anything at the expense of jeopardizing consistent long-term top line growth, which grows faster than the market. Now, having said that we will obviously as an organization we’ve always focused on being efficient and managing our costs prudently. So 2009 gave us a tremendous opportunity to take a peek at the areas of our operations and learned a few things and hopefully can expand that into the years ahead. You heard things that we have already done and some things we plan to do, which we will share with you as the year goes on. So we believe we can balance both top line growth and not starve that and expand margins. I see that we are in a position to be able to do that.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thank you.",3,"Okay. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now, we'll go to UBS's Derik De Bruin.",8,"Now, we'll go to UBS's Derik De Bruin.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hi, good morning.",3,"Hi, good morning.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Good morning, Derik.",3,"Good morning, Derik.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Could you talk about I know you said you were going to get a modest price increase in do you expect to realize a modest price increase in 2010. Could you put a little bit of color on that. And also I know you had some gains from the trial pricing in 2009",62,"Could you talk about I know you said you were going to get a modest price increase in do you expect to realize a modest price increase in 2010. Could you put a little bit of color on that. And also I know you had some gains from the trial pricing in 2009 and wondering how that impacts and your 2010 numbers?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yeah. So we were expecting a modest price increase in 2010 I think for planning purposes. We have assumed somewhere in the 1 to 2% middle of that. And I think on the other question on the trial that was a solvent in shortage in early part of 2009 like man",91,"Yeah. So we were expecting a modest price increase in 2010 I think for planning purposes. We have assumed somewhere in the 1 to 2% middle of that. And I think on the other question on the trial that was a solvent in shortage in early part of 2009 like many companies we benefited from that and that's included in the numbers. Now again, it wasn't that significant, but it did help us and the prices have come down, but that's in our guidance so we included that in our guidance.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. So I guess, let me start looking at going back to questions on some of your long-term growth rates, I guess you have talked about 4% for essentials and 6% for specialties and plus 10 each for Biotech and SAFC. I guess can you give us a little bit m",61,"Great. So I guess, let me start looking at going back to questions on some of your long-term growth rates, I guess you have talked about 4% for essentials and 6% for specialties and plus 10 each for Biotech and SAFC. I guess can you give us a little bit more color on how you think those will unfold during 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","In 2010 I think those targets that we gave you obviously we're still working on the premise that I think when we build the plan a few years back, we knew that those product areas globally should deliver and give us those type of sales 4, 6, 10, 10. Actual",167,"In 2010 I think those targets that we gave you obviously we're still working on the premise that I think when we build the plan a few years back, we knew that those product areas globally should deliver and give us those type of sales 4, 6, 10, 10. Actually that is tattooed in the business unit heads that run that.
Granted 2009 and 2010, 2009 particularly was a challenging year, coming out of 2009 going to 2010 we said that look, we should be able to make modest improvements over what we did in 2009 but going into beyond that our goal is still we have the ability to hit that 4, 6, 10, 10 and the investments that we have made continue to make both in R&D and in licensing in research Biotech should give us the capability. Second thing, we are building plant capacity in SAFC. We are rationalizing some sites to make sure we can become more efficient so that imminently doable.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. And I guess you have also had long-term model of plus 3% M&A bogie out there. Can you how do you see the deal market right now? Are you still looking to add technologies to the portfolio in this environment?",41,"Great. And I guess you have also had long-term model of plus 3% M&A bogie out there. Can you how do you see the deal market right now? Are you still looking to add technologies to the portfolio in this environment?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Absolutely. So that's one of our higher priorities especially as we going into this year is to continue to look at acquiring technology for the sake of growling our business, that could come in the form of acquisitions of companies or through partnerships",71,"Absolutely. So that's one of our higher priorities especially as we going into this year is to continue to look at acquiring technology for the sake of growling our business, that could come in the form of acquisitions of companies or through partnerships, licenses but that is going to be an area of focus for us going forward, especially with our balance sheet being as strong as it is right now.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Thank you very much.",5,"Great. Thank you very much.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now we'll take a question from John Roberts with Buckingham Research.",12,"Now we'll take a question from John Roberts with Buckingham Research.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Good morning, guys.",3,"Good morning, guys.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Good morning, John.",3,"Good morning, John.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","The positive impact of FX on sales in the quarter there was obviously a much higher impact on costs so you ended up with positive effect on sales but negative effect on EPS. And I assume that's again because of the lag with costs relative to sales in term",77,"The positive impact of FX on sales in the quarter there was obviously a much higher impact on costs so you ended up with positive effect on sales but negative effect on EPS. And I assume that's again because of the lag with costs relative to sales in terms of when you make things and put them in inventory. Your 1% revenue benefit from currency in 2010 that's in your guidance, what's your EPS assumption effective currency?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","As I mentioned in my remarks, that we have about $0.10 of positive contribution from exchange rate in 2010 and I am assuming exchange rates remain at current levels.",29,"As I mentioned in my remarks, that we have about $0.10 of positive contribution from exchange rate in 2010 and I am assuming exchange rates remain at current levels.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Does it go positive in the first quarter here?",9,"Does it go positive in the first quarter here?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Should be slightly positive in the first quarter, yes.",9,"Should be slightly positive in the first quarter, yes.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. And do sales actually have a negative currency effect in the back end of 2010 if rates stay the same since we've had a pretty quick movement here in currency in the last couple of months?",37,"Okay. And do sales actually have a negative currency effect in the back end of 2010 if rates stay the same since we've had a pretty quick movement here in currency in the last couple of months?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","No. It should be close. Certainly the earlier quarters will be the more advantageous ones but it should still be a modest advantage assuming it stays where it is today.",30,"No. It should be close. Certainly the earlier quarters will be the more advantageous ones but it should still be a modest advantage assuming it stays where it is today.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Through the year.",3,"Through the year.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think towards the tail end of the year that could be because as you know that the currency changed quite a bit in the first quarter.",27,"I think towards the tail end of the year that could be because as you know that the currency changed quite a bit in the first quarter.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Right. And your guidance includes the restructuring charge and do you assume any one-off positives that will offset that during 2010?",21,"Right. And your guidance includes the restructuring charge and do you assume any one-off positives that will offset that during 2010?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","No. the guidance does not include any one-time restructuring charges or any one-time benefits.",14,"No. the guidance does not include any one-time restructuring charges or any one-time benefits.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thank you.",3,"Okay. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now we'll open the floor up to Dmitry Silversteyn with Longbow Research.",13,"Now we'll open the floor up to Dmitry Silversteyn with Longbow Research.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Good morning, gentlemen. Congratulations on a nice finish to the year.",11,"Good morning, gentlemen. Congratulations on a nice finish to the year.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks, Dmitry.",2,"Thanks, Dmitry.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now we'll take a question from Isaac Ro with Leerink Swann. It looks like Dmitry's line disconnected.",18,"Now we'll take a question from Isaac Ro with Leerink Swann. It looks like Dmitry's line disconnected.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Good morning. Thank you for taking the question. First off, on your guidance for revenues of mid-single digit growth, could you maybe flush out a little bit more on what contribution you expect from pricing? I know you said you're actually maybe less this",81,"Good morning. Thank you for taking the question. First off, on your guidance for revenues of mid-single digit growth, could you maybe flush out a little bit more on what contribution you expect from pricing? I know you said you're actually maybe less this year but wondering what you realized in 2009 versus what you think it will number 2010 and maybe your outlook for the overall pricing environment by region. Is there an area where you're getting more price realization?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","As I mentioned, we expect somewhere between 1 to 2% in pricing in 2010. We got more than that in 2009. I believe it was about between 3.5%.",28,"As I mentioned, we expect somewhere between 1 to 2% in pricing in 2010. We got more than that in 2009. I believe it was about between 3.5%.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Great. Thanks. Secondly on the knockout rats business wondering what kind of infrastructure you might be looking to add this year either distribution or capacity and maybe as you think about early customers, is it fair to assume that pharma is reall",73,"Okay. Great. Thanks. Secondly on the knockout rats business wondering what kind of infrastructure you might be looking to add this year either distribution or capacity and maybe as you think about early customers, is it fair to assume that pharma is really the largest single end market opportunity over the long run but maybe at the initial onset you're seeing a more evenly dispersed level of interest from academics and drug companies.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yeah. Absolutely right. Longer term we put pharma will be likely more interest but initial term is balance between pharma and academic. To answer the early part of your question, do you have the infrastructure already to the type of work that we are doing",93,"Yeah. Absolutely right. Longer term we put pharma will be likely more interest but initial term is balance between pharma and academic. To answer the early part of your question, do you have the infrastructure already to the type of work that we are doing that's still is involuntary environment, small animals facility which we currently have. We don't believe we need to expand that rapidly until we get a feel for the direction we intend to take and we will tell you as we begin to plan and learn more about this.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Just lastly maybe China, how did that market perform in 2009 versus 2008 and what are your expectations this year?",21,"Great. Just lastly maybe China, how did that market perform in 2009 versus 2008 and what are your expectations this year?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","So if you look at China, India and Brazil, all three countries collectively they were up organically close to 20% year-over-year, so China is doing really well. We have this past year we put a distribution center in Shanghai and that is really helping us",129,"So if you look at China, India and Brazil, all three countries collectively they were up organically close to 20% year-over-year, so China is doing really well. We have this past year we put a distribution center in Shanghai and that is really helping us because we have a lot of our customers who are research laboratories in the area in Shanghai and so with that that helped us. We are also in the process of putting a packaging facility in Wushi which is an hour from Shanghai, so we're beginning to make the she felts in China and actually expanding our investments in India as well, so this year we'll be not only more in China but doing a heck of a lot more in India as well.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Thanks so much.",4,"Great. Thanks so much.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","You're welcome.",3,"You're welcome.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Dmitry Silversteyn rejoined us. Please go ahead.",7,"Dmitry Silversteyn rejoined us. Please go ahead.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Sorry, guys, technical difficulties there. My questions for most part have been answered but I would like to follow up on the comment you made, Jai, I think referencing your research and SAFC business. You mentioned something about the early stage project",93,"Sorry, guys, technical difficulties there. My questions for most part have been answered but I would like to follow up on the comment you made, Jai, I think referencing your research and SAFC business. You mentioned something about the early stage projects getting higher priority towards the end of the year from a pharmaceutical companies which helped your businesses. Do you see that trend continuing and kind of are we through the tough patch that we had in 2009 where most of the attention of your customers was turned to later stage projects?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think what we are finding is the early stage projects in terms of new inquiries for the new capacity is steadily increasing but in the industrial cell culture business the products already in the pipeline will we are seeing those accelerating at a faste",59,"I think what we are finding is the early stage projects in terms of new inquiries for the new capacity is steadily increasing but in the industrial cell culture business the products already in the pipeline will we are seeing those accelerating at a faster pace. So it is a mixed situation in the pharma and in the biopharma.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","So if I understand you correctly the biopharma is moving from the early stage to later stage which is beneficial to you as well because you are in industrial supplier of cell culture media and.",35,"So if I understand you correctly the biopharma is moving from the early stage to later stage which is beneficial to you as well because you are in industrial supplier of cell culture media and.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","And we got involved with a lot of early stage products a few years back.",15,"And we got involved with a lot of early stage products a few years back.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Right. And if the pharmaceutical arena the direction of where the money is being spent now is more amenable to your assets and your expert tees in terms of manufacturing custom chemicals?",32,"Right. And if the pharmaceutical arena the direction of where the money is being spent now is more amenable to your assets and your expert tees in terms of manufacturing custom chemicals?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","That is correct, the front end, yeah.",7,"That is correct, the front end, yeah.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Very good. Secondly, another thing that you said that was helping drive the results in Biotech was the synthetic DNA. I have been listening to these conference calls for several years and I think this is the first time I have heard synthetic DNA bei",101,"Okay. Very good. Secondly, another thing that you said that was helping drive the results in Biotech was the synthetic DNA. I have been listening to these conference calls for several years and I think this is the first time I have heard synthetic DNA being mentioned in a positive way in several years. Usually it is price declines in that product group that is causing to you under perform. Can you tell us what has change there had if anything or are we reaching an equilibrium point between supply and demand with the rationalization that took place in the industry.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","You're right, the rationalization of the industry, the supply and demand balance, that's one aspect. The second aspect also is that this is a very competitive business and we believe that we are now as competitive as anybody else in the marketplace and th",110,"You're right, the rationalization of the industry, the supply and demand balance, that's one aspect. The second aspect also is that this is a very competitive business and we believe that we are now as competitive as anybody else in the marketplace and the model that we are using has also changed. We are going allotted more for OEM for a number of people who are using this. We have entered into some partnerships and for competitive reasons obviously we can't share the names of them and those are all the contributing factors that give us the fourth quarter and we expect them to continue in 2010 as well.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. That makes sense. Finally, the price increasing I think in the answer to an earlier question you talked about looking at 1 to 2% price increases. Typically you talked about trying to get 2 to 3% in the research businesses, so I want to make sure the",69,"Okay. That makes sense. Finally, the price increasing I think in the answer to an earlier question you talked about looking at 1 to 2% price increases. Typically you talked about trying to get 2 to 3% in the research businesses, so I want to make sure the 1 to 2% was for the Company overall which would imply the research business would still be up 2 to 3%.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","That's accurate.",3,"That's accurate.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. And then my last question is on the guidance. Your guidance at the low end was $3. If you look at excluding the restructuring charge in 2009, you did $2.86. Are you going to get $0.10 from currency which moves you up to $2.96? So I am just trying to",70,"Okay. And then my last question is on the guidance. Your guidance at the low end was $3. If you look at excluding the restructuring charge in 2009, you did $2.86. Are you going to get $0.10 from currency which moves you up to $2.96? So I am just trying to understand the low end of the guidance. You are only looking to get $0.04 from organic growth of 5%?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","There are a few headwinds. We have obviously got tax rate changes. We entered the year at 29% in 2009. We gave you guidance of 30 to 31%. That's going to knock off about close to about I think about $0.07, $0.08, is that's take that into account. That mor",115,"There are a few headwinds. We have obviously got tax rate changes. We entered the year at 29% in 2009. We gave you guidance of 30 to 31%. That's going to knock off about close to about I think about $0.07, $0.08, is that's take that into account. That more than off sets the restructuring that you just mentioned. Then we are going to get more from supply chain and volumes and you can count on at least about $0.30 coming from that. Now, there is some additional spending, so we are planning in this guidance that we want to invest in some areas including R&D, so we have actually put that in this guidance.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. So $0.30 from the restructuring and the supply chain initiatives and the SG&A controls, $0.10 from.",17,"Okay. So $0.30 from the restructuring and the supply chain initiatives and the SG&A controls, $0.10 from.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","No, $0.30 includes volume, too.",5,"No, $0.30 includes volume, too.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. So you basically looking at about $0.20 of headwind is what it sounds like plus the tax rate?",19,"Okay. So you basically looking at about $0.20 of headwind is what it sounds like plus the tax rate?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Between the tax rate and some additional spending. I think that's in our plan because part of this thing is as we expanding margins, we want to reinvest for the future as well.",33,"Between the tax rate and some additional spending. I think that's in our plan because part of this thing is as we expanding margins, we want to reinvest for the future as well.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. So if 2009 was a year of hunkering down and trying to offset the headwinds that you were seeing across many of your businesses as well as foreign exchange. 2010 sounds like reinvestment year to take advantage of the some of the benefits foreign exch",48,"Okay. So if 2009 was a year of hunkering down and trying to offset the headwinds that you were seeing across many of your businesses as well as foreign exchange. 2010 sounds like reinvestment year to take advantage of the some of the benefits foreign exchange will provide.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I would say measured reinvestment and going back starting to go back to our normal growth rate.",17,"I would say measured reinvestment and going back starting to go back to our normal growth rate.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Sounds good. Thank you very much.",7,"Okay. Sounds good. Thank you very much.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you.",2,"Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Now we'll go to John Roberts with Buckingham Research.",10,"Now we'll go to John Roberts with Buckingham Research.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","The 45% web-based orders that you had in the quarter, could you break that into U.S. versus ex U.S.? U.S. is typically much higher so I don't know how high that is right now.",34,"The 45% web-based orders that you had in the quarter, could you break that into U.S. versus ex U.S.? U.S. is typically much higher so I don't know how high that is right now.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","The U.S. was in the mid-50% range, John.",9,"The U.S. was in the mid-50% range, John.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","And you still expect that to go higher and for international to eventually catch up to the U.S. level, too?",21,"And you still expect that to go higher and for international to eventually catch up to the U.S. level, too?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Absolutely. We're still shooting for that 50% range in the next three to five years.",15,"Absolutely. We're still shooting for that 50% range in the next three to five years.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","How high do you think U.S. will go in the next three to five years?",16,"How high do you think U.S. will go in the next three to five years?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think it will go up proportionately, so I would expect another roughly 5% in the U.S. as well.",19,"I think it will go up proportionately, so I would expect another roughly 5% in the U.S. as well.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Breaking 60 sometime in the next couple of years?",9,"Breaking 60 sometime in the next couple of years?
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yes.",1,"Yes.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thank you.",3,"Okay. Thank you.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","There are no further questions.",5,"There are no further questions.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I would like to just thank everybody for their participation, looking forward we do expect release results for the first quarter of 2010 before the market opens on April 22 of this year and similar to this morning we'll follow that with a conference call",111,"I would like to just thank everybody for their participation, looking forward we do expect release results for the first quarter of 2010 before the market opens on April 22 of this year and similar to this morning we'll follow that with a conference call that same day at 10:00 central time. We'll also be holding our annual business review at our life science and high technology center here in St. Louis on March 16. We certainly invite you to join us for that either in person or by joining us on the webcast and the information for that to register is also available on our website. That concludes today's conference.
"
303397,84111310,49586,"Sigma-Aldrich Corporation, Q4 2009 Earnings Call, Feb-10-2010",2010-02-10,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Ladies and gentlemen, once again that does conclude our conference for today. Thank you for your participation.",17,"Ladies and gentlemen, once again that does conclude our conference for today. Thank you for your participation. 

"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Good morning, my name is Karina and I will be your conference operator today. Today’s conference is being recorded. At this time I would like to welcome everyone to the Sigma-Aldrich first quarter 2010 results conference call. All lines have been placed",85,"Good morning, my name is Karina and I will be your conference operator today. Today’s conference is being recorded. At this time I would like to welcome everyone to the Sigma-Aldrich first quarter 2010 results conference call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks there will be a question and answer session. (Operator Instructions) I will now turn the call over to Mr. Kirk Richter, Vice President, Treasurer and Investor Relations contact. Please go ahead sir. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you and let me add my good morning to all of you and welcome you to our first quarter 2010 earnings conference call. With me today are Jai Nagarkatti, our Chairman, President and CEO, and Rakesh Sachdev, our Senior Vice President and CFO.After my",319,"Thank you and let me add my good morning to all of you and welcome you to our first quarter 2010 earnings conference call. With me today are Jai Nagarkatti, our Chairman, President and CEO, and Rakesh Sachdev, our Senior Vice President and CFO.
After my introductory comments Rakesh will review our first quarter 2010 performance and our outlook for all of 2010. Jai will follow that with an update on the activities that drive our 2010 financial expectations and position our company for a sustained longer term growth and report on what we have achieved on those activities in the first quarter. After completing those reviews we will open up the call for your questions and comments. We will be using a slide presentation as part of today’s call. That presentation can be viewed by accessing our Investor Relations website on sigma-aldrich.com. 
Before we begin these reviews, I do need to remind you that today’s comments will include forward looking statements about future activities and our expectations for sales, earnings, cash flow and other possible future results. While we believe these expectations are based on reasonable assumptions, actual results may differ materially due to any number of factors including the risk factors listed in our annual report on Form-10 K for the year ended December 31, 2009 and in the cautionary statement that is included in today’s release and in our slides. We have no plans to update these forward looking statements after this conference. 
Also SEC regulations require us to provide information on any non-GAAP financial measures covered in today’s conference. That information which consists of currently adjusted sales growth, profit and EPS results on both a pro forma and reported basis and free cash flow reconciled to net cash provided by operating activities is also contained in today's earnings release which is posted on our website. 
Now, I will ask Rakesh to begin our review. Rakesh?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks, Kirk, and good morning to everybody. I’m pleased to report that both our first quarter net income and diluted earnings per share set new quarterly records. And our first quarter 2010 sales of 572 million was roughly equivalent to the highest qua",1218,"Thanks, Kirk, and good morning to everybody. I’m pleased to report that both our first quarter net income and diluted earnings per share set new quarterly records. And our first quarter 2010 sales of 572 million was roughly equivalent to the highest quarterly amount achieved in our 35 years as a public company. Our reported sales growth was 10.2% with 5.8 percent points coming from currency and the other 4.4% from organic growth. A large portion of our 4.4% organic sales growth came from volume and only a small portion came from price. I’ll have more to say about that shortly.
Net income which hit the $100 million mark for the first time in the company’s history and diluted earnings per share both increased 19% on a reported basis and increased 10% on a currency -adjusted basis. And finally our free cash flow in the first quarter of $133 million was the best quarterly result in the last nine quarters. 
Our pre-tax income in the first quarter includes $6 million restructuring charge related to the consolidation of some of our SAFC facilities and the cost to eliminate about 100 positions to date through a small workforce reduction. This is part of our previously announced restructuring actions meant to increase the efficiencies of our operations and lower our overall fixed cost structure and the intent to record additional costs approximating $16 million related to these actions in 2010 and 2011. 
While these restructuring charges reduced our otherwise reportable earnings per share in the first quarter by $0.03, the benefits of these restructuring actions when fully implemented should add about $0.10 to our annual earnings per share.
Let’s now review our sales performance for the first quarter in more detail. After being challenged by economic conditions late in 2008 and through much of 2009, we saw several of our research businesses show good positive momentum driven by both recovery in the markets and several new product and marketing initiatives that we launched to gain share. 
Our organic growth was largely volume-driven as pricing was less than 1% which is lower on an overall basis than our traditional 2% contribution. Growth in sales to the academic customer sector remain modestly strong and consistent with that experienced in 2009 and was supplemented by improved growth in sales to the chemical industry, to the biotechnology customers and to research customers in smaller international countries served by our extensive dealer network in those markets. Sales to pharma customers however declined slightly.
Each of our major product initiatives and research from analytical to biology to material science showed good results with organic growth ranging from 4% to 10%. What is also different this quarter is that we saw positive growth in our traditional chemistry and biochemistry research products, these two highly profitable initiatives make up about a third of our total research sales, so we were pleased with this progress. 
On the other hand, sales of our lab essential products were weaker in the first quarter as prices for certain solvents that are no longer in short supply are now back to more normal market rates. As you can see on the slide overall, our research business grew about 3% in the first quarter. 
In SAFC, although we are comparing our results against a weak first quarter of 2009, we’re pleased with a 9% growth we experienced this quarter. We saw double digit growth of our custom pharma products driven by higher demand for high potency APIs and viral vectors which we were able to meet with new capacity from commercial scale plants that came online recently California and Wisconsin. We also absorbed substantially higher growth in our high-tech business driven by sales of metal organics for semiconductors, precursors for silicon semiconductors, gasses for flat panel displays and performance material coatings for solar applications. The electronics and solar markets are clearly showing signs of recovery.
From a geographical standpoint, we saw modest improvement in sales in North America and Europe. We saw continued strength in the Asia Pacific and Latin American markets as they grew 11% year-over-year. Not only did China, Brazil and India grow collectively over 20%, but we were also encouraged to see positive growth in Japan in our research business. 
As you can see in our margin analysis, our reported overall operating margin for the first quarter improved by 160 basis points to 25.7% from last year’s first quarter. The primary drivers for this improvement were improved volumes of higher margin products. Productivity improvements from our supply chain initiatives, management of our SG&A spending and a modest price contribution. While operating margin was also helped by about 60 basis points from currency, we did have a negative impact from the restructuring charge which reduced otherwise reportable margins by about 1% of sales.
As I mentioned earlier, we continue to generate strong free cash flow with the $133 million achieved in this first year’s quarter representing a 55% improvement over what we achieved in 2009’s first quarter. Our working capital initiatives, particularly in managing our inventory level considered to provide benefits enabling us to reduce our inventory month on hand by about 5% to 6.2 months. We believe there is room for further improvement as we plan to continue our momentum to reduce our inventory levels to about 6 months on hand. 
Our sales growth expectation for 2010, for mid-single digit organic growth hasn’t changed from our last report. With modestly improving market conditions and the traction provided by our new product offerings, geographic expansion and e-commerce initiatives, we fully expect to meet our sales outlook.
Many of you may be wondering about the impact of the recent volcanic activity on Iceland and its effect on our business in the international markets. Many of which are supplied by a distribution center in Germany. As of now, we do not expect a significant. Our inventory levels in the 17 countries we have distribution centers in, should help sustain our sales in those markets. We have made alternate plans to restock warehouses outside of Europe from our stocks in the United States and we’re able to move stock between countries in Europe to respond to demand. Our reports as of this morning indicate that normal flight activity is beginning to resume. 
Despite a stronger US dollar than what we previously forecast, I am pleased to say that we have increased our diluted earnings per share guidance for the full year to a new range of $3.05 to $3.20. This $0.05 increase over our initial forecast for 2010 comes from an expected continuation of stronger operating performance we enjoyed in the first quarter. This outlook excludes the impact of additional restructuring charges we intend to incur in 2010. 
Last quarter, we told you that currency should benefit us by about $0.10 in 2010; this benefit has declined given the strengthening of US dollar since our last outlook. We expect to see a margin improvement year-over-year although it may not be at the levels we saw this quarter as we begin to invest in a number of strategic organic growth initiatives. And lastly we have assumed an effective tax rate to be in the 30 to 31% range for our earnings outlook. 
Now, I’ll ask Jai to comment on our first quarter activities and 2010 activities, Jai?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you, Rakesh, and good morning everyone. Obviously we are pleased with the strong start. We had the sales and earnings growth this quarter. The team did a great job to service the needs of our customers as we saw signs of economic recovery in many of",1358,"Thank you, Rakesh, and good morning everyone. Obviously we are pleased with the strong start. We had the sales and earnings growth this quarter. The team did a great job to service the needs of our customers as we saw signs of economic recovery in many of our customer segments. Diagnostic customers and chemical industry were two segments that showed some promising signs of recovery even as large pharma accounts continue to remain under pressure. Our academic sector continued to show growth just as it did throughout last year. 
As we have often told you, in our research business there are no silver bullets. It is the combination of the many things that we consistently do well that makes the difference in the minds of our customers and influences their decisions to select Sigma-Aldrich as their preferred source for strategic products. 
In the first quarter, as markets began to recover we saw greater impact of contributions from many of the initiatives which we launched last year. For example, our expanded portfolio of highly validated antibodies are getting increased attention from researchers. Since the beginning of this year, we added another 4,500 new antibodies to our offerings. That brings Sigma-Aldrich’s life science total prestige antibody portfolio to 8,300 covering 6,900 human protein targets and further expands the company’s overall monoclonal and polyclonal antibody offering to over 30,000. 
Next, the adoption rate of the award winning Zinc Finger Nuclease technology is growing rapidly. The success of this technology is being leveraged in custom animal models and other applications such as engineered cell lines. Earlier this week, we announced an extension to our award winning CompoZr [ph] product offering with the global release with the CompoZr targeted integration kit. This kit provides a powerful transgene integration and expression of any gene in any human cell line. As we have told you in the past, we are excited about the Zinc Finger Nuclease technology and the numerous opportunities this brings to help make Sigma-Aldrich a key player in the fast growth life science space. 
In Analytical chemistry, we expanded the range of analytical standards for environmental, petrochemical and forensic testing and launched a new line of phytopharmaceuticals and certified reference materials to our exhausted product offering. Earlier this year, we also announced an agreement with Pfizer to offer approximately a 100 of their small molecule products to life science researches for target characterization, assay development and screening, and most recently a distribution agreement with Bolinger Ingleheim to offer a line of biodegradable polymers for biomaterial research. These are just a few example of our commitment to enable research that helps improve the quality of life. 
Our SAFC business also delivered strong positive organic sales growth for the third successive quarter. This resulted from a strong growth in high-tech, which was fairly depressed most of last year and in the SAFC biosciences businesses there’ll be some more projects moved towards the developmental pipeline. 
If you participated in our investor day in March, you heard about our launch of new strategic initiatives at the beginning of this year, to drive our top line growth to 4% above the market rate of the next five years. Let me recap some of these initiatives and their expected contribution towards this 4% incremental sales growth and then comment on our results in the first quarter. 
Our innovation initiatives will focus on faster growth segments within analytical, biology and the material science products within our chemistry offering. Collectively these cover 60% of our research product sales. Here we expect to add 1.5 percentage points to the total company growth above the normal market growth rate of 3% to 4%. 
In analytical we serve researchers in areas that include environmental research, food, beverage testing and product analysis in pharmaceutical and biotech applications. In biology, our products help life scientists understand complex biological pathways and systems and living cells. 
And finally in material science, our traditional chemistry product as additional applications in a variety of devices from flat panel displays to the cell phones that many of us use. Emerging market expansion with a focus on opportunities in the Asia Pacific and Latin American markets is expected to provide another incremental 1% in growth. We plan to do this by expanding our sales coverage in the region, adding distribution capacity and beginning to package many of our products locally. 
Just last year, we quadrupled our distribution capacity in China and we plan to triple our distribution and packaging capacity in India this year. Our go to market strategies that involve expanding our e-commerce capabilities and realignment of our sales force efforts are expected to add one-half of 1% to our otherwise reportable growth. 
We have also launched some marketing effectiveness program such as TOP which stands for Transaction Optimization Program and Quick Start which will increase awareness of our traditional chemistry and biochemistry product and believe that these efforts are now gaining contraction. And finally in our SAFC unit, the new and differentiating capacity which we have added in recent years to respond to customers evolving needs should add another 1% to our growth rate. 
Collectively these initiatives are expected to drive our organic sales growth to a 7% to 8% range in the next five years. We believe that current market growth is somewhat less than the 3% to 4% range, but all indication show that it is improving over 2009 performance. But our goal has always been and is to take market share. So, how are we doing early in 2010? Our long term organic growth goals are in excess of 10% for both analytical and material science and above 7% for our biology business. 
Though it’s early days, but after one quarter, we believe that we are largely on track with organic sales growth ranging from between 4% to 10% in these product initiative areas. I have already mentioned some of our product initiatives that are and expected to continue contributing to growth.
In the Asia Pacific and Latin America and international markets, we had reported growth of 23% with organic growth of 11%. In our focused markets of China, India and Brazil combined organic growth was a strong 21%. 
Within our SAFC unit, we continue to see a strong indicator of future growth in our booked orders for future delivery. We delivered a fair amount of what was booked at December 31st in the first quarter and booked orders again increased and are now 5% higher than it was at the end of December 2009. We feel this is a positive indicator of improved performance from this unit in 2010.
Sales through our e-commerce channel continue to grow over 2009 levels and that was in 47% of our reset sales in the first quarter, up from 45% for all of 2009. We averaged over 20,000 new registrations each month during the first quarter, we also added over 30 new direct business to business connections in the first three months of this year and we achieved a new record of over 3.5 million visits to our website in March 2010 with an average monthly increase of almost 15% from prior year levels.
That now brings me back to the forecast for 2010. Rakesh has already discussed our current expectations of mid-single digit organic sales growth. The increased diluted, adjusted, earnings per share before restructuring charges in a range of $3.05 to $3.20 and a free cash flow in excess of $350 million. Let me assure you that the entire Sigma-Aldrich team is committed to achieving these results and I look forward to updating you on our progress in our next conference call. 
I want to thank you all for your ongoing interest in our company. We are focused on enabling science to improve the quality of life and on improving our performance at both the top and bottom line through our activities and product innovation, geographic expansion, and new e-commerce capabilities. So, on behalf of Kirk, Rakesh and all our colleagues around the world I want to thank you for your joining us today. 
Now let’s open up the call for your comments and questions. Thank you.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Thank you. (Operator Instructions) We will take the first question from Dan Leonard with First Analysis, please go ahead.",19,"Thank you. (Operator Instructions) We will take the first question from Dan Leonard with First Analysis, please go ahead.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you, I just have a couple of questions on your margins. So, your gross margin improved by nearly 300 basis points sequentially from the fourth quarter on almost the same level of revenue. Can you help me better understand why the big jump on similar",47,"Thank you, I just have a couple of questions on your margins. So, your gross margin improved by nearly 300 basis points sequentially from the fourth quarter on almost the same level of revenue. Can you help me better understand why the big jump on similar revenue?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Sure. Well, if you look at what happened in Q1 versus Q4, we were helped by FX - if you look at what’s happened to our sales, we lost about 13 or $14 million because of FX quarter-over-quarter where we actually gained a little bit on the profit side, so",127,"Sure. Well, if you look at what happened in Q1 versus Q4, we were helped by FX - if you look at what’s happened to our sales, we lost about 13 or $14 million because of FX quarter-over-quarter where we actually gained a little bit on the profit side, so when you convert that as a percent of sales that clearly help us. And the earnings that happened between Q4 and Q1 is that we had a fairly significant conversion on the higher volumes. So FX reduced the sales, we actually had a real volume growth in Q1 versus Q4 and we had a very nice conversion on that, so if you look at both of those factors that gave us a nice pop on the margin.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","And then Rakesh, is there any reason we should assume that the 53% gross margin is not a sustainable metric for the balance of the year?",26,"And then Rakesh, is there any reason we should assume that the 53% gross margin is not a sustainable metric for the balance of the year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Well, you know the thing that - if you look at what we have done in Q1 and you look at the run rate and say why should it be different for the full-year? There are a couple of things I would like to point out. One, I think the FX based on where we are sit",150,"Well, you know the thing that - if you look at what we have done in Q1 and you look at the run rate and say why should it be different for the full-year? There are a couple of things I would like to point out. One, I think the FX based on where we are sitting right now and where the Euro is and who knows where it’s going to go, we are going to lose something on the margins for the balance of the year because of currency. And I think the second thing is, we fully intend to actually increase some of our SG&A spending in the balance of the year, although that won’t affect gross margin, but it will affect operating margin. So, I think we will see a little bit of tempering from the levels we saw in Q1 for the balance of the year. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay, thank you.",3,"Okay, thank you.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Okay.",1,"Okay. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","And next we will go to Quintin Lai with Robert W. Baird.",12,"And next we will go to Quintin Lai with Robert W. Baird.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hi, good morning and congrats on the good starts of the year. Jai, could you give us a little update on what you are seeing with respect to stimulus related spending and then for your outlook here in 2010, what do you expect with respect to like, pharma d",56,"Hi, good morning and congrats on the good starts of the year. Jai, could you give us a little update on what you are seeing with respect to stimulus related spending and then for your outlook here in 2010, what do you expect with respect to like, pharma demand for the back half of the year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Okay, let me start off with the stimulus thing Quintin, I think. As we mentioned earlier the academic sector continued to be strong in the first quarter. And certainly the stimulus money, it flowed through, certainly it would come through our US academic",149,"Okay, let me start off with the stimulus thing Quintin, I think. As we mentioned earlier the academic sector continued to be strong in the first quarter. And certainly the stimulus money, it flowed through, certainly it would come through our US academic accounts. So, again, since we are mostly in the consumable area, can’t point out and say that a lot of this increase is the cause of the stimulus money. But, we do see the volume going up, so that could be one indication that yes, we are seeing some benefit especially in the US academic accounts. 
The second thing is, when - through the SAFC supply solutions when we see some orders coming in for a specific applications that has been funded the NIH and so on, we can probably attribute that to stimulus type of funding. So, we are seeing a little bit of that. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you.",2,"Thank you.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","So, coming back to the second question on the pharma outlook. We realize that there is consolidation that’s ongoing in this industry, everybody reads that in the paper, but this is not any different. We have seen this in the past and historically what h",154,"So, coming back to the second question on the pharma outlook. We realize that there is consolidation that’s ongoing in this industry, everybody reads that in the paper, but this is not any different. We have seen this in the past and historically what has happened is, it generally comes back as pharma readjusts and refocuses their research effort, and having said that, when we use the word pharma, we use it to specifically talk about the large pharma and small molecules. There are other aspects of the pharma applications such as diagnostics and biopharmaceutical companies which continue to be doing well. So, overall I would say that we feel that I think while we may be losing some interim share because of consolidations in the large pharma, the outlook overall for overall pharma applications is what we would expect - what we saw in Q1 to continue in the rest of the year.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you for that Jai. With respect to new product uptake, given some of the new ad campaigns that you have and the fact that the Sigma has been a leader in new technology adoption with respect to the internet and all the different types of communication",88,"Thank you for that Jai. With respect to new product uptake, given some of the new ad campaigns that you have and the fact that the Sigma has been a leader in new technology adoption with respect to the internet and all the different types of communication tools out there, do you - is it still going to take the same type of lead time for a new product to get traction or do you think the customers are getting educated maybe faster through these new communication media?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think, certainly I think that the internet - the advantage that we have is they don’t have to - people don’t have to wait for the catalog cycles for new products to be made up for customers to be made aware of new products. To that extent, we are in",119,"I think, certainly I think that the internet - the advantage that we have is they don’t have to - people don’t have to wait for the catalog cycles for new products to be made up for customers to be made aware of new products. To that extent, we are introducing new products on our website, increasing the content and raising the awareness campaigns and certainly we see that the response is much more faster than that. I mentioned earlier that our TOP program and the Quick Start program to gauge what is the effectiveness of these types of e-commerce-based promotions that we are doing, how quickly is it getting attention and awareness? So, we see some positive signs.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Super, thank you.",4,"Okay. Super, thank you.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","And next we will go to Derik de Bruin with UBS.",11,"And next we will go to Derik de Bruin with UBS.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hi, good morning.",3,"Hi, good morning.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Hi Derik.",2,"Hi Derik.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Hi.",1,"Hi.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey, so if you were to take out the (inaudible) last year. What was it like for (inaudible) organic growth?",20,"Hey, so if you were to take out the (inaudible) last year. What was it like for (inaudible) organic growth?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think we would have grown probably also in the low single digits?",13,"I think we would have grown probably also in the low single digits?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yeah.",1,"Yeah.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay, that’s good. And I guess at what point - I mean on FX, where does the Euro need to fall to versus the dollar before it comes to a point where you really don’t think you can offset the headwind in the currencies?",44,"Okay, that’s good. And I guess at what point - I mean on FX, where does the Euro need to fall to versus the dollar before it comes to a point where you really don’t think you can offset the headwind in the currencies?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Right now, I think, as of this morning again, there was some (inaudible) I think they are setting at a 1.33 and I think - it could go down little more, I think we can absorb it. I think we have mentioned that. But certainly if it starts going close to 1.3",96,"Right now, I think, as of this morning again, there was some (inaudible) I think they are setting at a 1.33 and I think - it could go down little more, I think we can absorb it. I think we have mentioned that. But certainly if it starts going close to 1.30 and below then we have look at some other actions, but I think we are committed as a company to deal with that and figure out a way of making sure that we provide the shareholders with the returns that they are looking for.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Right. I guess when you look at the - you talked about increasing the R&D spend on - for like projects, I mean, you have typically hovered around 3% of sales, 2.9 somewhere in that area, is that kind of the - is that kind of how you see that’s rolling o",73,"Right. I guess when you look at the - you talked about increasing the R&D spend on - for like projects, I mean, you have typically hovered around 3% of sales, 2.9 somewhere in that area, is that kind of the - is that kind of how you see that’s rolling out going forward, or do you expect any - really any significant, greater spending on R&D kind of in the out year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think additionally we have spent on over all basis 33% of our revenues. Now again, as we have pointed out in the past, if we apply the R&D to our manufactured products, that number is much higher obviously and as we mentioned our focus is going to be -",140,"I think additionally we have spent on over all basis 33% of our revenues. Now again, as we have pointed out in the past, if we apply the R&D to our manufactured products, that number is much higher obviously and as we mentioned our focus is going to be - introduce products in our target areas of biology, chemistry and material science. So, we will continue to do that. What we don’t include in the 3% spend on R&D is the incremental money that we also spend to in-license new technology and new capability to add new products like the Atlas antibodies that I talked about the Prestige line. That is also a significant amount of money. (inaudible) always another example. So, I think overall I think we invest I believe on a comparable basis to others in the industry.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Mean that the - your overall proprietary or yourself manufactured product mix is about or product percentage is about what?",19,"Mean that the - your overall proprietary or yourself manufactured product mix is about or product percentage is about what?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","60%.",2,"60%.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","60%. Okay, great. Thank you.",6,"60%. Okay, great. Thank you.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","The following question comes from Dmitry Silversteyn [ph] with Longbow Research. Please go ahead.",14,"The following question comes from Dmitry Silversteyn [ph] with Longbow Research. Please go ahead.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Good morning guys. Can you talk a little bit about the pricing? Why lower than normal 2% that you used to see it last year?",25,"Good morning guys. Can you talk a little bit about the pricing? Why lower than normal 2% that you used to see it last year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","One of the big factors was, last year as I mentioned, at this time of the year there was a shortage of a particular solvent acetonitrile and so the prices were quite high. So this year we are not enjoying that price benefit. Prices are back to - more back",77,"One of the big factors was, last year as I mentioned, at this time of the year there was a shortage of a particular solvent acetonitrile and so the prices were quite high. So this year we are not enjoying that price benefit. Prices are back to - more back to normal. So, if you feel peel that effect of what happened to that solvent out then we would be probably closer to the normal pricing levels.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Do you think there is opportunity to raise prices later in the year?",13,"Do you think there is opportunity to raise prices later in the year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","We look at selectively, so the value that we are offering and we really price for value rather than just pricing the products. And historically I think the industry has achieved somewhere around 1.5 to 2% in pricing and I would expect that that should con",49,"We look at selectively, so the value that we are offering and we really price for value rather than just pricing the products. And historically I think the industry has achieved somewhere around 1.5 to 2% in pricing and I would expect that that should continue even this year.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay great. And in Japan, sales were up this quarter, it was kind of positive to see your price there. Now, can you provide a little bit more color on what’s changing in Japan?",34,"Okay great. And in Japan, sales were up this quarter, it was kind of positive to see your price there. Now, can you provide a little bit more color on what’s changing in Japan?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Our research sales were up this past quarter. As you know, I mean, this is probably going to be the first Japan is going to see a positive real GDP growth. So I think there is just some optimism more than that has been in the past. As you know, last sever",142,"Our research sales were up this past quarter. As you know, I mean, this is probably going to be the first Japan is going to see a positive real GDP growth. So I think there is just some optimism more than that has been in the past. As you know, last several years, Japan has had negative GDP growth. And I think - so one, we are benefitting from the overall economy. I think the second thing that’s happening is our business model has been tweaked a little bit there. I think we have said we are doing more direct sales in Japan than we have done in the past. In the past we have gone entirely through distributors and I think that has opened up several doors for us with several customers and that is beginning to help us as well. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Thank you very much.",4,"Thank you very much.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Next, we will go to Isaac Ro with Leerink Swann.",10,"Next, we will go to Isaac Ro with Leerink Swann. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hi, good morning. Thanks for taking the question. Just first, I wanted to ask you the question on free cash and CapEx. I saw CapEx this quarter; I think it was just 18 million. So you are pacing certainly little below your guidance for the year. I am wond",117,"Hi, good morning. Thanks for taking the question. Just first, I wanted to ask you the question on free cash and CapEx. I saw CapEx this quarter; I think it was just 18 million. So you are pacing certainly little below your guidance for the year. I am wondering if there is anything may be in the next quarter or two that will kind of ramp that back up to sort of the full year number, pacing that we are looking for in and specifically as we look - for the rest of the year, do you see outside of your free cash guidance, should some of your CapEx projects kind of come in lower than expected?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","So, yes it was little lower than what we had originally forecast but I think several of the projects - this is a timing issue. We are still forecasting that is going to get caught up in the subsequent quarters. We are still forecasting close to about a $1",68,"So, yes it was little lower than what we had originally forecast but I think several of the projects - this is a timing issue. We are still forecasting that is going to get caught up in the subsequent quarters. We are still forecasting close to about a $130 million this year. Should that change in any way I am sure, we will bring that to your attention. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Got it, thanks. And so, is it fair to say, I mean, is the China packaging facility may be one of those items that would be a factor in the timing?",31,"Got it, thanks. And so, is it fair to say, I mean, is the China packaging facility may be one of those items that would be a factor in the timing?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yes. So, yeah, the China investment will begin sort of later in the year or soon. We have not started that investment, so that is all going to be happening in the next three quarters.",35,"Yes. So, yeah, the China investment will begin sort of later in the year or soon. We have not started that investment, so that is all going to be happening in the next three quarters. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Got it, thanks. And then just may be lastly on technology. I know you guys are making pretty good progress with this SAGE Labs and I saw the new product I think a week ago. Wondering how are you looking at capital investment for that as this year progress",78,"Got it, thanks. And then just may be lastly on technology. I know you guys are making pretty good progress with this SAGE Labs and I saw the new product I think a week ago. Wondering how are you looking at capital investment for that as this year progresses, is that a sizeable investment for you this year or is it really about kind of building up the fans and getting a - a following in the industry.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think the latter statement is very astute. Building up the fans and getting a following in the industry is the approach we would take.",25,"I think the latter statement is very astute. Building up the fans and getting a following in the industry is the approach we would take. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great. Okay, thanks very much.",5,"Great. Okay, thanks very much.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","We will now go to Peter Kazoni [ph] with KeyBanc Capital Markets.",12,"We will now go to Peter Kazoni [ph] with KeyBanc Capital Markets.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey guys, good start for the year.",7,"Hey guys, good start for the year. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks.",1,"Thanks.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thanks Peter.",2,"Thanks Peter. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","In your previous guidance I believe you had a $0.10 FX taped in. Can you give us maybe some more color on what is driving your increased guidance, with the - as you maintain organic growth outlook. Are cost savings kind of ahead of schedule here? Or can y",55,"In your previous guidance I believe you had a $0.10 FX taped in. Can you give us maybe some more color on what is driving your increased guidance, with the - as you maintain organic growth outlook. Are cost savings kind of ahead of schedule here? Or can you kind of discuss the delta there?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","As I said, we did give a guidance of $0.10. We expect that number to be less now. May be about half as much and that could fluctuate back and forth depending on what the Euro does. But really the benefit that we are getting as we said, if you look at our",129,"As I said, we did give a guidance of $0.10. We expect that number to be less now. May be about half as much and that could fluctuate back and forth depending on what the Euro does. But really the benefit that we are getting as we said, if you look at our previous guidance. I think we are seeing a stronger product mix. We are clearly seeing a higher margin from some of the products that we are selling, more traditional products. I think there the growth is a little stronger. I think if you look at our performance in Q1, if you just roll that into the full year, I think for us to give an extra $0.05 was, we take this as very appropriate, very doable.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Great, thanks. And then, can you may be talk about little bit of what you are seeing fine chemicals market. It should really go to organic growth here up 9%. Do you feel this kind of rate is sustainable and how should we look at the remainder of the year",60,"Great, thanks. And then, can you may be talk about little bit of what you are seeing fine chemicals market. It should really go to organic growth here up 9%. Do you feel this kind of rate is sustainable and how should we look at the remainder of the year as far as in may be a sequential pickup here?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think, again, one of the ways we track the health of that business obviously is in the booked order for future delivery, again as I mentioned earlier, I think that number is still increasing from the levels that we saw at December. The other thing is, w",111,"I think, again, one of the ways we track the health of that business obviously is in the booked order for future delivery, again as I mentioned earlier, I think that number is still increasing from the levels that we saw at December. The other thing is, within the SAFC unit, as certain sectors like the high tech sector comes back on, we see renewed interest. The new products that we are launching, the new capacity that we have launched and the interest that has been generated because of that differentiating capability, we feel fairly positive that I think this trend should continue for at least the balance of this year.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","That’s helpful. And, may be just - could you may be quantify the growth you saw in the high tech business?",22,"That’s helpful. And, may be just - could you may be quantify the growth you saw in the high tech business?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Well, our growth in the high tech business was like about 40 or 50%.",14,"Well, our growth in the high tech business was like about 40 or 50%. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Wow. All right, great guys. That’s all I have.",9,"Wow. All right, great guys. That’s all I have.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","(Operator Instructions) we will now go to Jon Wood with Jefferies.",11,"(Operator Instructions) we will now go to Jon Wood with Jefferies. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Hey, thanks a lot. So Rakesh, back on the - I guess it is an absorption question. If you look at the inventories, we’re down 25 million sequentially and revenue was flat sequentially. I would have thought that that would be an absorption issue, but it s",58,"Hey, thanks a lot. So Rakesh, back on the - I guess it is an absorption question. If you look at the inventories, we’re down 25 million sequentially and revenue was flat sequentially. I would have thought that that would be an absorption issue, but it sounds like you actually got a benefit from absorption in the quarter?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yes, we did get some benefit from absorption in the quarter. But really what drove more of it was just the product mix. We are just selling more products that have higher margin.",33,"Yes, we did get some benefit from absorption in the quarter. But really what drove more of it was just the product mix. We are just selling more products that have higher margin.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. And specifically, I mean, SAFC I know it is typically a lower gross margin and that grew quite a bit faster than the research business. So, what - is high tech just better mix within SAFC and was there any movements within the research business?",46,"Okay. And specifically, I mean, SAFC I know it is typically a lower gross margin and that grew quite a bit faster than the research business. So, what - is high tech just better mix within SAFC and was there any movements within the research business?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Yeah, I think as I said, within the research business in our chemistry, our traditional chemistry, biochemistry business showed good growth in the first quarter. That’s our bread and butter business and whenever we see good growth there it’s actually",45,"Yeah, I think as I said, within the research business in our chemistry, our traditional chemistry, biochemistry business showed good growth in the first quarter. That’s our bread and butter business and whenever we see good growth there it’s actually close to the bottom line. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay, thanks. On the capital structures, does the guidance factor in any changes in the debt structure later in the year. I know you have got some notes due in September, so what are your plans for restructuring that or refinancing it?",42,"Okay, thanks. On the capital structures, does the guidance factor in any changes in the debt structure later in the year. I know you have got some notes due in September, so what are your plans for restructuring that or refinancing it?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Now, the guidance did not contemplate any significant shift in our debt structure. As you know that we have $100 million of privately placed debt coming due later this fall and of course, we will be working through that and come back to you with what we a",60,"Now, the guidance did not contemplate any significant shift in our debt structure. As you know that we have $100 million of privately placed debt coming due later this fall and of course, we will be working through that and come back to you with what we are doing to do as far as taking on more long term debt.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. And then what would be - if the R&D tax credit were extended or renewed, what kind of impact would that have on your tax rate guidance for the year?",31,"Okay. And then what would be - if the R&D tax credit were extended or renewed, what kind of impact would that have on your tax rate guidance for the year?
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","I think it has traditionally been a one-half to six-tenths of a point in the effective tax rate.",19,"I think it has traditionally been a one-half to six-tenths of a point in the effective tax rate.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Analysts","Okay. Thanks guys.",3,"Okay. Thanks guys. 
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","It appears we have no further questions at this time. I would now like to turn the call back over to Mr. Richter for any additional or closing remarks.",29,"It appears we have no further questions at this time. I would now like to turn the call back over to Mr. Richter for any additional or closing remarks.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Executives","Thank you and we certainly want to thank everybody that participated this morning. Looking forward, we do expect to release results for the second quarter of 2010 before the market opens on July 22, and we will again follow that with the conference call t",56,"Thank you and we certainly want to thank everybody that participated this morning. Looking forward, we do expect to release results for the second quarter of 2010 before the market opens on July 22, and we will again follow that with the conference call that same day at 10’o clock Central Time. This concludes today’s conference.
"
303397,99876556,57578,"Sigma-Aldrich Corporation, Q1 2010 Earnings Call, Apr 22, 2010",2010-04-22,"Earnings Calls","Sigma-Aldrich Corporation","Operator","Once again, this does conclude today’s conference, we do thank you for joining us.",14,"Once again, this does conclude today’s conference, we do thank you for joining us. 

"
